Source:http://linkedlifedata.com/resource/pubmed/id/10095431
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1999-4-28
|
pubmed:abstractText |
Osteosarcoma is one of the most commonly biopsied primary tumor of bone. High-grade osteosarcomas in particular exhibit a wide spectrum of cytogenetic changes. Molecular cytogenetic studies on osteosarcomas have shown that genomic amplification, especially of both the TP53-binding MDM2 gene and the flanking SAS gene, plays an important role in the biology of these tumors. We applied CGH in order to obtain a global view of DNA-sequence losses and gains in osteosarcoma. CGH was performed on 20 high-grade medullary osteosarcomas (13 primary tumors prior to chemotherapy, 5 tumors after chemotherapy, 2 established cell lines [MB63, HOS58]) using genomic DNA of snap-frozen tumor specimens. CGH revealed DNA copy number aberrations, mostly gains, in all the tumors studied with an average of 18.5 aberrations/tumor (range 8-32). High-level amplifications were observed in all cases (average 4.1 amplifications/tumor [range 1-10]). Amplicons affecting at least five tumors were mapped to 1p21-31 (9/20 cases), 3q25-qter (6/20), 6p12-21 (6/20), 8q12-qter (10/20), 12p11-12 (9/20), 12q12-15 (enclosing MDM2 and SAS loci, 7/20). Losses were most frequently seen at 3p, 10q, 11p and 13 (all 10/20). In conclusion, our CGH data indicated that genomic amplification plays an important role in the biology of osteosarcoma. CGH demonstrated the complexity of genetic aberrations in osteosarcomas. The detection of novel non-random DNA amplifications in our study has defined regions for further targeted molecular genetic research aimed at identifying those oncogenes that are characteristic of osteosarcoma development.
|
pubmed:language |
ger
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0070-4113
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
82
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
184-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10095431-Bone Neoplasms,
pubmed-meshheading:10095431-Chromosome Aberrations,
pubmed-meshheading:10095431-Chromosome Mapping,
pubmed-meshheading:10095431-Humans,
pubmed-meshheading:10095431-Loss of Heterozygosity,
pubmed-meshheading:10095431-Nuclear Proteins,
pubmed-meshheading:10095431-Osteosarcoma,
pubmed-meshheading:10095431-Proto-Oncogene Proteins,
pubmed-meshheading:10095431-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:10095431-Proto-Oncogenes,
pubmed-meshheading:10095431-Tumor Cells, Cultured
|
pubmed:year |
1998
|
pubmed:articleTitle |
[Comparative genomic hybridization (CGH) for detecting a heretofore undescribed amplified chromosomal segment in high-grade medullary osteosarcoma].
|
pubmed:affiliation |
Institut für Pathologie, Westfälischen Wilhelms-Universität Münster.
|
pubmed:publicationType |
Journal Article,
English Abstract
|